SLC5A2 and type 2 diabetes mellitus: Thus far, the results from SCORED and SOLOIST suggest that an increase in SGLT1 inhibition when added to SGLT2 inhibition may contribute to the reduction in MI and stroke in patients with type 2 diabetes [5, 6].